To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Avalyn Pharma nets $35.5m Series B
Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing.
